bcr yes (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
90
Structured Review
ATCC
bcr yes
Bcr Yes, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcr+yes/Ustilago+maydis+(DeCandolle)+Corda/pm41188783-57-129-177
Average 90 stars, based on 4 article reviews
Bcr Yes, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcr+yes/Ustilago+maydis+(DeCandolle)+Corda/pm41188783-57-129-177
Average 90 stars, based on 4 article reviews
bcr yes - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Expressing:Article Title: UHRF1 and NF-κB signaling in prostate cancer progression insights from bioinformatics and experimental validation. Article Snippet: .. Survival analyses, multivariate Cox modeling, and time-dependent Table 1 The correlation between UHRF1 expression and clinical parameters in prostate cancer (n = 493) Clinical parameters Low UHRF1(n = 247) High UHRF1(n = 246) P value Age(year) Mean ± std 60.69 ± 6.97 61.29 ± 6.70 0.793 Median (minimaxi) 61(41–78) 62(46–78) Gleason score 6 35(14.2%) 15(6.1%) < 0.0001 7 = 3 + 4 93(37.7%) 55(22.4%) 7 = 4 + 3 49(19.8%) 48(19.5%) 8 24(9.7%) 48(19.5%) 9–10 46(18.6%) 80(32.5%) PSA(ng/mL) Mean ± std 9.91 ± 11.15 11.93 ± 12.05 0.2868 Median (minimaxi) 7(0.7–87) 7.9(1.5–107) Race Black 35(14.2%) 23(9.4%) 0.373 White 199(80.6%) 209(84.8%) Yellow 5(2.0%) 7(2.9%) Other 8(3.2%) 7(2.9%) T stage T2 115(46.6%) 71(28.9%) 0.00036 T3 125(50.6%) 166(67.5%) T4 3(1.2%) 7(2.8%) Unknown 4(1.6%) 2(0.8%) Radiation Yes 22(8.9%) 37(15.0%) 0.05 No 225(91.1%) 209(85.0%) Cell Culture:Article Title: UHRF1 and NF-κB signaling in prostate cancer progression insights from bioinformatics and experimental validation. Article Snippet: .. Survival analyses, multivariate Cox modeling, and time-dependent Table 1 The correlation between UHRF1 expression and clinical parameters in prostate cancer (n = 493) Clinical parameters Low UHRF1(n = 247) High UHRF1(n = 246) P value Age(year) Mean ± std 60.69 ± 6.97 61.29 ± 6.70 0.793 Median (minimaxi) 61(41–78) 62(46–78) Gleason score 6 35(14.2%) 15(6.1%) < 0.0001 7 = 3 + 4 93(37.7%) 55(22.4%) 7 = 4 + 3 49(19.8%) 48(19.5%) 8 24(9.7%) 48(19.5%) 9–10 46(18.6%) 80(32.5%) PSA(ng/mL) Mean ± std 9.91 ± 11.15 11.93 ± 12.05 0.2868 Median (minimaxi) 7(0.7–87) 7.9(1.5–107) Race Black 35(14.2%) 23(9.4%) 0.373 White 199(80.6%) 209(84.8%) Yellow 5(2.0%) 7(2.9%) Other 8(3.2%) 7(2.9%) T stage T2 115(46.6%) 71(28.9%) 0.00036 T3 125(50.6%) 166(67.5%) T4 3(1.2%) 7(2.8%) Unknown 4(1.6%) 2(0.8%) Radiation Yes 22(8.9%) 37(15.0%) 0.05 No 225(91.1%) 209(85.0%) |